Abstract
Chronic hepatitis B virus (HBV) infection has a variable course leading to cirrhosis and hepatocellular carcinoma (HCC). The pathogenesis and clinical outcome of HBV infection are strictly dependent on both viral factors, such as life cycle and genotypic variants, and host immune response (i.e. viral persistence). Although therapy of hepatitis B is evolving, which between single and/or combined agents are most effective, how long therapy should last, which criteria should be used to start or continue and switch or stop therapy are to be defined. Two major groups of therapies are currently utilized for chronic hepatitis: immunomodulatory (interferons) and antivirals (nucleoside and nucleotide analogues), all with their own advantages and limitations. In fact, the development of specific antiviral therapies has provoked the appearance of a relevant problem: drug resistances. The emerged antiviral drug-resistant strains of HBV leads to a poor prognosis for infected patients. Thus, many basic and clinical research challenges remain in defining optimal means of management of viral hepatitis B and its related liver diseases. This paper provides a review of new available and developing treatment options for HBV associated liver diseases. In the near future the most realistic therapeutic option for the majority of patients with HBV infection will be combination and/or long-term use of new and stronger antiviral drugs, if they maintain good safety profiles, achieve low resistance rates and will be available at lower prices.
Keywords: HBV, IFNs, nucleoside/nucleotide analogues, drug resistance, therapy, viral variants
Current Medicinal Chemistry
Title: Viral Hepatitis B: Established and Emerging Therapies
Volume: 15 Issue: 9
Author(s): Clara Balsano and Anna Alisi
Affiliation:
Keywords: HBV, IFNs, nucleoside/nucleotide analogues, drug resistance, therapy, viral variants
Abstract: Chronic hepatitis B virus (HBV) infection has a variable course leading to cirrhosis and hepatocellular carcinoma (HCC). The pathogenesis and clinical outcome of HBV infection are strictly dependent on both viral factors, such as life cycle and genotypic variants, and host immune response (i.e. viral persistence). Although therapy of hepatitis B is evolving, which between single and/or combined agents are most effective, how long therapy should last, which criteria should be used to start or continue and switch or stop therapy are to be defined. Two major groups of therapies are currently utilized for chronic hepatitis: immunomodulatory (interferons) and antivirals (nucleoside and nucleotide analogues), all with their own advantages and limitations. In fact, the development of specific antiviral therapies has provoked the appearance of a relevant problem: drug resistances. The emerged antiviral drug-resistant strains of HBV leads to a poor prognosis for infected patients. Thus, many basic and clinical research challenges remain in defining optimal means of management of viral hepatitis B and its related liver diseases. This paper provides a review of new available and developing treatment options for HBV associated liver diseases. In the near future the most realistic therapeutic option for the majority of patients with HBV infection will be combination and/or long-term use of new and stronger antiviral drugs, if they maintain good safety profiles, achieve low resistance rates and will be available at lower prices.
Export Options
About this article
Cite this article as:
Balsano Clara and Alisi Anna, Viral Hepatitis B: Established and Emerging Therapies, Current Medicinal Chemistry 2008; 15(9) . https://dx.doi.org/10.2174/092986708783955383
DOI https://dx.doi.org/10.2174/092986708783955383 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Treatment and Outcome of Pulmonary Arterial Hypertension in HIVInfected Patients: A Review of the Literature
Current HIV Research Research Strategies for Pain in Lumbar Radiculopathy Focusing on Acid-Sensing Ion Channels and Their Toxins
Current Topics in Medicinal Chemistry High Throughput Screening Assay to Identify Modulators of IL-17 Expression
Combinatorial Chemistry & High Throughput Screening Fine Tuning Therapeutic Targeting of the Sphingolipid Biosynthetic Pathway to Treat Atherosclerosis
Current Vascular Pharmacology Antidiabetic and Renoprotective Effects of Ethyl Acetate Fraction of <i>Mimosa pudica</i> Linn. Leaves Extract in Streptozotocin-Induced Diabetic Mice
Current Bioactive Compounds Patients with Hereditary Hemorrhagic Telangectasia (HHT) Exhibit a Deficit of Polymorphonuclear Cell and Monocyte Oxidative Burst and Phagocytosis: A Possible Correlation with Altered Adaptive Immune Responsiveness in HHT
Current Pharmaceutical Design Interleukin-12: An Update on its Immunological Activities, Signaling and Regulation of Gene Expression
Current Immunology Reviews (Discontinued) Crystallography of Membrane Proteins, Major Targets in Drug Design
Mini-Reviews in Medicinal Chemistry Involvement of the Transforming Growth Factor β in the Pathogenesis of Hereditary Hemorrhagic Telangiectasia
Current Pharmaceutical Design Virally Encoded Polymerases as Targets for Chemotherapy: Application to HIV and HBV
Current Medicinal Chemistry - Anti-Infective Agents Non-Replicating Viral Vector-Based AIDS Vaccines: Interplay Between Viral Vectors and the Immune System
Current HIV Research Micro RNA: An Epigenetic Regulator of Type 2 Diabetes
MicroRNA Gene Clusters, Molecular Evolution and Disease: A Speculation
Current Genomics Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Polymer Particulates in Drug Delivery
Current Pharmaceutical Design Design, Synthesis and Potent Pharmaceutical Applications of Glycodendrimers:A Mini Review
Current Drug Discovery Technologies Monoclonal Antibodies in the Treatment of Leukemia
Current Molecular Medicine Anti-Inflammatory and Anti-Apoptotic Effects of Levosimendan in Decompensated Heart Failure: A Novel Mechanism of Drug-Induced Improvement in Contractile Performance of the Failing Heart
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Immunogenicity in Protein and Peptide Based-Therapeutics: An Overview
Current Protein & Peptide Science Editorial: Regenerative Medicine for Retinal Diseases
Current Tissue Engineering (Discontinued)